TMO vs TEVA vs A Stock Comparison

Thermo Fisher Scientific, Teva Pharmaceutical Industries and Agilent Technologies Prices as of Nov 13, 2026 Peers: Industry group
A Agilent Technologies, Inc.
$173.91 -0.1% 1M +18.4% 1Y
Market cap
$49.04B
P/E
34.1x
Revenue (TTM)
$7.37B
Div. yield
0.60%
Life Sciences Tools Healthcare
6 wins

Head to Head

12 decided of 12

Agilent Technologies leads on 6 of the 12 questions below (Agilent Technologies 6, Teva Pharmaceutical Industries 4, Thermo Fisher Scientific 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionTMOTEVAALeader
Larger companyMarket capitalisation $259.44B $51.97B $49.04B TMO
Cheaper on earningsLower P/E, profitable companies only 36.6x 102.6x 34.1x A
Cheaper on forward earningsLower price / next fiscal year consensus EPS 27.0x 22.7x 26.6x TEVA
Faster revenue growthRevenue growth, trailing twelve months +8.3% +2.7% +8.6% A
More profitableNet margin, trailing twelve months 14.9% 2.9% 19.5% A
Better return on capitalReturn on invested capital 8.0% 5.9% 13.1% A
Less leveragedLower net debt / EBITDA 3.1x 5.2x 1.1x A
Higher dividend yieldTrailing dividend yield 0.26% 0.00% 0.60% A
Better 1-year returnPrice return, last 12 months +20.7% +74.4% +18.4% TEVA
Better 5-year returnAnnualised price return, 5 years +2.0%/yr +36.2%/yr +1.6%/yr TEVA
Less volatileAnnualised volatility, 1 year 30.7% 33.4% 32.8% TMO
Higher overall scoreMean of the five percentile scores vs peers 60/100 62/100 61/100 TEVA

Percentile Scorecard

TMOTEVAA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisTMOTEVAA
Valuation 62 #94 of 243 82 #120 of 660 60 #98 of 243
Growth 41 #136 of 228 68 #201 of 619 37 #144 of 228
Profitability 82 #40 of 222 86 #87 of 595 93 #17 of 222
Financial Health 31 #172 of 248 11 #608 of 683 53 #117 of 248
Shareholder Returns 82 #29 of 158 – 64 #57 of 158
Overall 60 62 61
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • TEVA ranked among 695 companies in Pharmaceuticals and Biotechnology
  • A ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodTMOTEVAASPY
1 month +4.0%+9.3%-0.1% -2.0%
3 months +19.1%+21.1%+17.1% -2.8%
6 months +59.7%+29.9%+55.7% +2.0%
Year to date +20.8%+42.7%+27.8% +10.6%
1 year +20.7%+74.4%+18.4% +12.2%
3 years +52.5%+399.9%+55.8% +68.1%
3 years, per year +15.1%+71.0%+15.9% +18.9%
5 years +10.2%+368.3%+8.1% +61.4%
5 years, per year +2.0%+36.2%+1.6% +10.1%
10 years +362.9%+9.6%+275.0% +248.5%
10 years, per year +16.6%+0.9%+14.1% +13.3%

Risk

MeasureTMOTEVAASPY
Volatility, 1Y 30.7%33.4%32.8% 13.6%
Downside volatility, 1Y 29.2%27.5%28.1% 13.9%
Beta vs S&P 500, 1Y 0.710.590.91 1.00
Return / volatility, 1Y 0.672.230.56 0.90
Max drawdown, 5Y -41.5%-43.7%-39.6% -25.4%
From 52-week high -3.0%0.0%-4.2% -3.2%
52-week high $721.63$44.54$181.54 $779.14
52-week low $438.34$24.21$110.24 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleTMOTEVAA
P/E now vs peer median 36.6xmedian 26.5x 102.6xmedian 17.0x 34.1xmedian 26.5x
P/S now vs peer median 5.5xmedian 2.7x 3.0xmedian 8.4x 6.7xmedian 2.7x
EV/EBITDA now vs peer median 25.5xmedian 18.4x 26.7xmedian 14.6x 26.8xmedian 18.4x
P/FCF now vs peer median 34.2xmedian 25.4x 42.0xmedian 19.0x 38.7xmedian 25.4x
P/B now vs peer median 4.7xmedian 2.5x 6.5xmedian 2.0x 6.7xmedian 2.5x
PEG now vs peer median 4.84median 0.98 3.39median 0.43 3.46median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsTMOTEVAA
Revenue $47.35B $17.23B $7.37B
Gross profit $19.45B $9.22B $3.97B
Operating income $8.47B $1.44B $1.64B
Net income $7.09B $508.00M $1.44B
Free cash flow $7.60B $1.24B $1.27B
R&D $1.40B $1.76B $485.00M
EPS (diluted) $19.06 $0.43 $5.09
Cash & equivalents $5.46B $4.09B $1.76B
Total debt $41.37B $16.72B $3.95B
Shares (diluted) 371.00M 1.18B 283.00M
Enterprise value $236.08B $36.94B $41.92B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricTMOTEVAA
P/E 36.6x 102.6x 34.1x
P/FCF 34.2x 42.0x 38.7x
P/Operating cash flow 27.8x 29.4x 30.5x
P/S 5.5x 3.0x 6.7x
P/B 4.7x 6.5x 6.7x
P/Tangible book 7.1x 11.1x 7.6x
EV/EBITDA 25.5x 26.7x 26.8x
EV/EBIT 34.8x 45.0x 31.3x
EV/Revenue 6.2x 3.7x 6.9x
EV/FCF 38.8x 52.3x 40.4x
EV/Operating cash flow 31.6x 36.5x 31.8x
PEG (3Y EPS CAGR) 4.84 3.39 3.46

Growth

14 metrics
MetricTMOTEVAA
Revenue growth (1Y) 8.3% 2.7% 8.6%
Revenue CAGR (3Y) 2.9% 4.1% 1.8%
Gross profit growth (1Y) 7.8% 9.7% 11.2%
Gross profit CAGR (3Y) 4.0% 9.6% 3.7%
Operating income growth (1Y) 12.8% -21.5% 13.5%
Operating income CAGR (3Y) 7.2% 46.4% 5.1%
Net income growth (1Y) 7.9% -23.3% 18.0%
Net income CAGR (3Y) 6.2% 30.3% 8.3%
EPS growth (1Y) 9.7% -30.1% 18.9%
EPS CAGR (3Y) 7.6% 30.2% 9.8%
Operating cash flow growth (1Y) 21.9% 66.0% 7.6%
Operating cash flow CAGR (3Y) 4.5% 15.2% -1.9%
Free cash flow growth (1Y) 24.3% 113.8% 16.5%
Free cash flow CAGR (3Y) 5.1% 26.7% -3.7%

Profitability

14 metrics
MetricTMOTEVAA
Gross margin 41.1% 53.5% 53.8%
EBITDA margin 24.4% 14.0% 25.9%
Operating margin 17.9% 8.3% 22.2%
Pretax margin 16.7% 2.1% 22.5%
Net margin 14.9% 2.9% 19.5%
FCF margin 16.0% 7.2% 17.2%
Operating cash flow margin 19.7% 10.3% 21.8%
Return on equity 13.2% 6.5% 19.9%
Return on assets 6.2% 1.3% 10.7%
Return on invested capital 8.0% 5.9% 13.1%
Return on capital employed 8.5% 5.9% 14.6%
Asset turnover 0.4x 0.4x 0.5x
Cash conversion (OCF / net income) 1.3x 3.5x 1.1x
Stock comp / revenue 0.7% 1.0% 1.8%

Financial Health

11 metrics
MetricTMOTEVAA
Debt / assets 36.2% 41.8% 28.3%
Debt / equity 0.8x 2.1x 0.5x
Net debt / EBITDA 3.1x 5.2x 1.1x
Debt / FCF 5.4x 13.5x 3.1x
Liabilities / assets 52.1% 80.1% 47.3%
Equity / assets 47.9% 19.9% 52.7%
Interest coverage 12.0x – 15.5x
Current ratio 1.8x 0.9x 2.1x
Quick ratio 1.2x 0.5x 1.4x
Cash ratio 0.4x 0.3x 0.8x
Altman Z-score 4.18 1.02 5.77

Shareholder Returns

7 metrics
MetricTMOTEVAA
Dividend yield 0.3% – 0.6%
Net buyback yield 1.6% – 0.6%
Shareholder yield 1.8% 0.0% 1.2%
Payout ratio (earnings) 9.5% – 19.9%
Payout ratio (FCF) 8.9% – 22.6%
Dividend growth (1Y) 8.0% – 2.1%
Dividend CAGR (3Y) 10.1% – 3.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusTMOTEVAA
Forward P/E 27.0xFY2026 22.7xFY2026 26.6xFY2026
EPS, next fiscal year $25.92FY2026 $1.96FY2026 $6.54FY2026
EPS growth, next FY +13.3%FY2026 -33.1%FY2026 +17.0%FY2026
EPS growth, the year after +2.2% +65.3% +0.2%
Revenue, next fiscal year $50.12BFY2026 $15.89BFY2026 $7.87BFY2026
Revenue growth, next FY +12.5%FY2026 -8.0%FY2026 +15.3%FY2026
Revenue growth, the year after -2.7% +16.5% -5.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersTMOTEVAA
Held by institutions 90.2% 62.7% 92.6%
Institutions holding 2,627 672 1,126
Change in shares held, QoQ +0.8% +8.6% +3.2%
Institutions buying 1,145 359 601
Institutions selling 1,145 192 351
Buyers to sellers 1.00 1.87 1.71

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

TMOTEVAA
TMO 1.00 0.26 0.74
TEVA 0.26 1.00 0.19
A 0.74 0.19 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, TMO, TEVA and A?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Thermo Fisher Scientific (TMO) $259.44B, Teva Pharmaceutical Industries (TEVA) $51.97B, Agilent Technologies (A) $49.04B.

Which stock is cheaper, TMO, TEVA and A?

Agilent Technologies (A) trades on the lowest price-to-earnings ratio (Thermo Fisher Scientific (TMO) 36.6x, Teva Pharmaceutical Industries (TEVA) 102.6x, Agilent Technologies (A) 34.1x). On next year's consensus earnings, Teva Pharmaceutical Industries (TEVA) is cheapest (Thermo Fisher Scientific (TMO) 27.0x, Teva Pharmaceutical Industries (TEVA) 22.7x, Agilent Technologies (A) 26.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Agilent Technologies (A) grew revenue fastest over the trailing twelve months: Thermo Fisher Scientific (TMO) +8.3%, Teva Pharmaceutical Industries (TEVA) +2.7%, Agilent Technologies (A) +8.6%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Thermo Fisher Scientific (TMO) 14.9%, Teva Pharmaceutical Industries (TEVA) 2.9%, Agilent Technologies (A) 19.5%). On return on invested capital, Agilent Technologies (A) leads (Thermo Fisher Scientific (TMO) 8.0%, Teva Pharmaceutical Industries (TEVA) 5.9%, Agilent Technologies (A) 13.1%).

Which stock has performed better?

Over the past year Teva Pharmaceutical Industries (TEVA) returned the most: Thermo Fisher Scientific (TMO) +20.7%, Teva Pharmaceutical Industries (TEVA) +74.4%, Agilent Technologies (A) +18.4%. Over five years, Teva Pharmaceutical Industries (TEVA) compounded fastest (Thermo Fisher Scientific (TMO) +2.0%/yr, Teva Pharmaceutical Industries (TEVA) +36.2%/yr, Agilent Technologies (A) +1.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Agilent Technologies (A) has the highest dividend yield: Thermo Fisher Scientific (TMO) 0.26%, Teva Pharmaceutical Industries (TEVA) 0.00%, Agilent Technologies (A) 0.60%. Teva Pharmaceutical Industries (TEVA) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Thermo Fisher Scientific (TMO) 30.7%, Teva Pharmaceutical Industries (TEVA) 33.4%, Agilent Technologies (A) 32.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, TMO, TEVA and A?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.